Biotech Report: Evotec und Qiagen behauptet, Biontech unter Druck | (shareribs.com) Frankfurt / New York 08.05.2024 - Die Biotechnologiewerte zeigen sich am Mittwoch uneinheitlich. Vita34 und Biontech geben nach, Evotec legen leicht zu. Auch an der Wall Street zeigt... ► Artikel lesen |
QIAGEN N.V.: QIAGEN und FBI entwickeln im Bereich Forensik gemeinsam neuen Test für digitale PCR-Plattform QIAcuity | Neuer digitaler PCR-Assay soll Ergebnisse der DNA-Analyse menschlicher Proben für die Forensik und Personenidentifizierung verbessern // DNA-Quantifizierung ermöglicht Strafverfolgungsbehörden und Forensikern... ► Artikel lesen |
Biotech Report: Evotec und Qiagen unter Druck, US-Sektor verliert | (shareribs.com) Frankfurt / New York 06.05.2024 - Biotech-Aktien bewegen sich zum Wochenauftakt überwiegend im Minus. Im deutschen Handel geben Evotec und Qiagen nach. An der Wall Street kann Arrowhead... ► Artikel lesen |
Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen |
Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen |
Kymera Therapeutics, Inc.: Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting | KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294... ► Artikel lesen |
Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen |
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) | CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the... ► Artikel lesen |
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones | Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation... ► Artikel lesen |